Jonathan L. Moore
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jonathan L. Moore has a total of 106 co-authors. Here are the top co-authors by number of shared publications:
Aida Santaolalla
3 shared publications- Andrew R. Davies
Department of Upper Gastrointestinal and General Surgery, Guy’s and St Thomas’ Hospital , London
3 shared publications Mieke Van Hemelrijck
3 shared publicationsA. Jacques
2 shared publicationsA. Qureshi
Department of Medical Oncology, Guy’s & St Thomas’ Hospital, London, UK
2 shared publicationsB. Gill-Barman
2 shared publications
Latest Publications
- Open Access
- 17 September 2026
- Published by Springer Nature in European Radiology
- p. 1-11
Comparing the utility of FDG PET-CT and contrast-enhanced CT in patients with oesophagogastric adenocarcinoma treated with neoadjuvant chemotherapy
Background: 2-deoxy-2[ 18 F]fluoro-D-glucose positron emission tomography-CT (FDG PET-CT) is established in staging oesophagogastric adenocarcinoma. It has an emerging role in assessing response to neoadjuvant chemotherapy (NACT) but its benefits over contrast-enhanced CT (CECT) remain unknown. This study aimed to compare the accuracy of CECT and FDG PET-CT in predicting pathological tumour (ypT) stage, nodal (ypN) stage, pathological treatment response and detecting distant metastases. Materials and methods: Single-centre cohort study of patients with oesophagogastric adenocarcinoma who underwent both CECT and FDG PET-CT before and after NACT. Radiological response was evaluated using the change in oesophageal thickness on CECT and the change in SUVmax for FDG PET-CT. Receiver-operator-characteristic analysis was performed, and the area under the curve (AUC) was calculated to determine the accuracy of CECT and FDG PET-CT to predict pathological stage and treatment response. Results: 105 patients were identified and 92 underwent surgical resection. For inclusion, FDG PET-CT and CECT had to be performed contemporaneously (same scanner, same hospital visit) ( n = 66). CECT and FDG PET-CT were comparable for predicting ypT stage (AUC 0.65 vs. 0.62, p = 0.76) and ypN stage (AUC 0.52 vs. 0.53, p = 0.92). FDG PET-CT was a better predictor of pathological tumour response (AUC 0.72 vs. 0.51, p = 0.041). Eight patients had metastatic disease identified on restaging imaging; 8 (100%) by FDG PET-CT; 4 (50.0%) by CECT ( p = 0.076). Conclusions: CECT and FDG PET-CT are clinically useful for restaging following completion of NACT. FDG PET-CT was more accurate at response assessment and identified metastatic disease more frequently. The choice of imaging modality depends on balancing clinical utility with cost and accessibility. Key Points: Question: Is FDG PET-CT or contrast-enhanced CT more accurate in predicting pathological stage and treatment response following completion of neoadjuvant chemotherapy in patients with oesophagogastric adenocarcinoma? Findings: CECT and FDG PET-CT were comparable for predicting pathological stage. FDG PET-CT was a better predictor of tumour response and distant metastases than CECT . Clinical relevance: CECT and FDG PET-CT are both useful for restaging after completion of NACT. FDG PET-CT may be most useful for patients with advanced disease where the likelihood of occult metastases is greatest and response assessment may impact clinical decision-making .
- 17 September 2026
- Published by Springer Nature in European Radiology
- p. 1-11
Open AccessComparing the utility of FDG PET-CT and contrast-enhanced CT in patients with oesophagogastric adenocarcinoma treated with neoadjuvant chemotherapy
Background: 2-deoxy-2[ 18 F]fluoro-D-glucose positron emission tomography-CT (FDG PET-CT) is established in staging oesophagogastric adenocarcinoma. It has an emerging role in assessing response to neoadjuvant chemotherapy (NACT) but its benefits over contrast-enhanced CT (CECT) remain unknown. This study aimed to compare the accuracy of CECT and FDG PET-CT in predicting pathological tumour (ypT) stage, nodal (ypN) stage, pathological treatment response and detecting distant metastases. Materials and methods: Single-centre cohort study of patients with oesophagogastric adenocarcinoma who underwent both CECT and FDG PET-CT before and after NACT. Radiological response was evaluated using the change in oesophageal thickness on CECT and the change in SUVmax for FDG PET-CT. Receiver-operator-characteristic analysis was performed, and the area under the curve (AUC) was calculated to determine the accuracy of CECT and FDG PET-CT to predict pathological stage and treatment response. Results: 105 patients were identified and 92 underwent surgical resection. For inclusion, FDG PET-CT and CECT had to be performed contemporaneously (same scanner, same hospital visit) ( n = 66). CECT and FDG PET-CT were comparable for predicting ypT stage (AUC 0.65 vs. 0.62, p = 0.76) and ypN stage (AUC 0.52 vs. 0.53, p = 0.92). FDG PET-CT was a better predictor of pathological tumour response (AUC 0.72 vs. 0.51, p = 0.041). Eight patients had metastatic disease identified on restaging imaging; 8 (100%) by FDG PET-CT; 4 (50.0%) by CECT ( p = 0.076). Conclusions: CECT and FDG PET-CT are clinically useful for restaging following completion of NACT. FDG PET-CT was more accurate at response assessment and identified metastatic disease more frequently. The choice of imaging modality depends on balancing clinical utility with cost and accessibility. Key Points: Question: Is FDG PET-CT or contrast-enhanced CT more accurate in predicting pathological stage and treatment response following completion of neoadjuvant chemotherapy in patients with oesophagogastric adenocarcinoma? Findings: CECT and FDG PET-CT were comparable for predicting pathological stage. FDG PET-CT was a better predictor of tumour response and distant metastases than CECT . Clinical relevance: CECT and FDG PET-CT are both useful for restaging after completion of NACT. FDG PET-CT may be most useful for patients with advanced disease where the likelihood of occult metastases is greatest and response assessment may impact clinical decision-making .
- 20 January 2024
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 42 (3) , 367-368
Reply to R. Sun et al
- 20 January 2024
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 42 (3) , 367-368
Reply to R. Sun et al
- 1 October 2023
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 41 (28) , 4522-4534
Pathologic Lymph Node Regression After Neoadjuvant Chemotherapy Predicts Recurrence and Survival in Esophageal Adenocarcinoma: A Multicenter Study in the United Kingdom
PURPOSE: There is limited evidence regarding the prognostic effects of pathologic lymph node (LN) regression after neoadjuvant chemotherapy for esophageal adenocarcinoma, and a definition of LN response is lacking. This study aimed to evaluate how LN regression influences survival after surgery for esophageal adenocarcinoma. METHODS: Multicenter cohort study of patients with esophageal adenocarcinoma treated with neoadjuvant chemotherapy followed by surgical resection at five high-volume centers in the United Kingdom. LNs retrieved at esophagectomy were examined for chemotherapy response and given a LN regression score (LNRS)—LNRS 1, complete response; 2, 50% residual tumor; and 5, no response. Survival analysis was performed using Cox regression adjusting for confounders including primary tumor regression. The discriminatory ability of different LN response classifications to predict survival was evaluated using Akaike information criterion and Harrell C-index. RESULTS: In total, 17,930 LNs from 763 patients were examined. LN response classified as complete LN response (LNRS 1 ≥1 LN, no residual tumor in any LN; n = 62, 8.1%), partial LN response (LNRS 1-3 ≥1 LN, residual tumor ≥1 LN; n = 155, 20.3%), poor/no LN response (LNRS 4-5; n = 303, 39.7%), or LN negative (no tumor/regression; n = 243, 31.8%) demonstrated superior discriminatory ability. Mortality was reduced in patients with complete LN response (hazard ratio [HR], 0.35; 95% CI, 0.22 to 0.56), partial LN response (HR, 0.72; 95% CI, 0.57 to 0.93) or negative LNs (HR, 0.32; 95% CI, 0.25 to 0.42) compared with those with poor/no LN response. Primary tumor regression and LN regression were discordant in 165 patients (21.9%). CONCLUSION: Pathologic LN regression after neoadjuvant chemotherapy was a strong prognostic factor and provides important information beyond pathologic TNM staging and primary tumor regression grading. LN regression should be included as standard in the pathologic reporting of esophagectomy specimens.
- 1 October 2023
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 41 (28) , 4522-4534
Pathologic Lymph Node Regression After Neoadjuvant Chemotherapy Predicts Recurrence and Survival in Esophageal Adenocarcinoma: A Multicenter Study in the United Kingdom
PURPOSE: There is limited evidence regarding the prognostic effects of pathologic lymph node (LN) regression after neoadjuvant chemotherapy for esophageal adenocarcinoma, and a definition of LN response is lacking. This study aimed to evaluate how LN regression influences survival after surgery for esophageal adenocarcinoma. METHODS: Multicenter cohort study of patients with esophageal adenocarcinoma treated with neoadjuvant chemotherapy followed by surgical resection at five high-volume centers in the United Kingdom. LNs retrieved at esophagectomy were examined for chemotherapy response and given a LN regression score (LNRS)—LNRS 1, complete response; 2, 50% residual tumor; and 5, no response. Survival analysis was performed using Cox regression adjusting for confounders including primary tumor regression. The discriminatory ability of different LN response classifications to predict survival was evaluated using Akaike information criterion and Harrell C-index. RESULTS: In total, 17,930 LNs from 763 patients were examined. LN response classified as complete LN response (LNRS 1 ≥1 LN, no residual tumor in any LN; n = 62, 8.1%), partial LN response (LNRS 1-3 ≥1 LN, residual tumor ≥1 LN; n = 155, 20.3%), poor/no LN response (LNRS 4-5; n = 303, 39.7%), or LN negative (no tumor/regression; n = 243, 31.8%) demonstrated superior discriminatory ability. Mortality was reduced in patients with complete LN response (hazard ratio [HR], 0.35; 95% CI, 0.22 to 0.56), partial LN response (HR, 0.72; 95% CI, 0.57 to 0.93) or negative LNs (HR, 0.32; 95% CI, 0.25 to 0.42) compared with those with poor/no LN response. Primary tumor regression and LN regression were discordant in 165 patients (21.9%). CONCLUSION: Pathologic LN regression after neoadjuvant chemotherapy was a strong prognostic factor and provides important information beyond pathologic TNM staging and primary tumor regression grading. LN regression should be included as standard in the pathologic reporting of esophagectomy specimens.
- Open Access
- 10 November 2021
- Published by Springer Nature in Research Square
Patient Perspectives on Key Symptoms and Preferences for Follow-up After Upper Gastro-intestinal Cancer Surgery
Purpose: Long-lasting symptoms and reductions in quality of life are common after oesophago-gastric surgery. Post-operative follow-up has traditionally focussed on tumour recurrence and survival, but there is a growing need to also identify and treat functional sequelae to improve patients’ recovery.Methods: An electronic survey was circulated via a British national charity for patients undergoing oesophago-gastric surgery and their families. Patients were asked about post-operative symptoms they deemed important to their quality of life, as well as satisfaction and preferences for post-operative follow-up. Differences between satisfied and dissatisfied patients with reference to follow-up were assessed.Results: Among 362 respondents with a median follow-up of 58 months since surgery (range 3-412), 36 different symptoms were reported as being important to recovery and quality of life after surgery, with a median 13 symptoms per patient. Most (84%) respondents indicated satisfaction with follow-up. Unsatisfied patients were more likely to have received shorter follow-up than 5 years (27% among unsatisfied patient vs. 60% among satisfied patients, p<0.001) and were less likely to have seen a dietitian as part of routine follow-up (37% vs. 58%, p=0.005).Conclusion: This patient survey highlights preferences regarding follow-up after oesophago-gastrectomy. Longer follow-up and dietician involvement improved patient satisfaction. Patients reported being concerned by a large number of gastrointestinal and non-gastrointestinal symptoms, highlighting the need for multidisciplinary input and a consensus on how to manage the poly-symptomatic patient.
- 10 November 2021
- Published by Springer Nature in Research Square
Open AccessPatient Perspectives on Key Symptoms and Preferences for Follow-up After Upper Gastro-intestinal Cancer Surgery
Purpose: Long-lasting symptoms and reductions in quality of life are common after oesophago-gastric surgery. Post-operative follow-up has traditionally focussed on tumour recurrence and survival, but there is a growing need to also identify and treat functional sequelae to improve patients’ recovery.Methods: An electronic survey was circulated via a British national charity for patients undergoing oesophago-gastric surgery and their families. Patients were asked about post-operative symptoms they deemed important to their quality of life, as well as satisfaction and preferences for post-operative follow-up. Differences between satisfied and dissatisfied patients with reference to follow-up were assessed.Results: Among 362 respondents with a median follow-up of 58 months since surgery (range 3-412), 36 different symptoms were reported as being important to recovery and quality of life after surgery, with a median 13 symptoms per patient. Most (84%) respondents indicated satisfaction with follow-up. Unsatisfied patients were more likely to have received shorter follow-up than 5 years (27% among unsatisfied patient vs. 60% among satisfied patients, p<0.001) and were less likely to have seen a dietitian as part of routine follow-up (37% vs. 58%, p=0.005).Conclusion: This patient survey highlights preferences regarding follow-up after oesophago-gastrectomy. Longer follow-up and dietician involvement improved patient satisfaction. Patients reported being concerned by a large number of gastrointestinal and non-gastrointestinal symptoms, highlighting the need for multidisciplinary input and a consensus on how to manage the poly-symptomatic patient.
- 11 October 2016
- Published by Elsevier in Annals of Oncology
- Vol. 27 (suppl_6) , vi160
Brain metastasis in advanced colorectal cancer: Results from the South Australian metastatic colorectal cancer (SAmCRC) registry
Background: The SAmCRC registry has been enrolling patients since February 2006. Patterns of care have evolved leading to longer survival. Brain metastasis is considered rare in mCRC and surveillance imaging does not routinely include the brain. The reported rate ranges from 0.6% to 3.2%. We have analysed the SAmCRC registry to assess the frequency of brain metastasis in the SA population and the timing of presentation, which may guide the timing of appropriate surveillance assessments.
- 11 October 2016
- Published by Elsevier in Annals of Oncology
- Vol. 27 (suppl_6) , vi160
Brain metastasis in advanced colorectal cancer: Results from the South Australian metastatic colorectal cancer (SAmCRC) registry
Background: The SAmCRC registry has been enrolling patients since February 2006. Patterns of care have evolved leading to longer survival. Brain metastasis is considered rare in mCRC and surveillance imaging does not routinely include the brain. The reported rate ranges from 0.6% to 3.2%. We have analysed the SAmCRC registry to assess the frequency of brain metastasis in the SA population and the timing of presentation, which may guide the timing of appropriate surveillance assessments.